Advertisement

Topics

Pfizer Release: FDA Advisory Committee Votes In Favor Of XELJANZ (Tofacitinib Citrate) For The Treatment Of Active Psoriatic Arthritis

20:00 EDT 3 Aug 2017 | BioSpace

  Life Sciences Jobs   ...

Original Article: Pfizer Release: FDA Advisory Committee Votes In Favor Of XELJANZ (Tofacitinib Citrate) For The Treatment Of Active Psoriatic Arthritis

NEXT ARTICLE

More From BioPortfolio on "Pfizer Release: FDA Advisory Committee Votes In Favor Of XELJANZ (Tofacitinib Citrate) For The Treatment Of Active Psoriatic Arthritis"

Quick Search
Advertisement